![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Abraxis Loses European Appeal on Patent Extension
Abraxis Loses European Appeal on Patent Extension
![PatentsTabLabel.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/PatentsTabLabel.gif?t=1579739301&width=430)
April 1, 2019
Small changes to a drug’s active ingredient aren’t sufficient grounds to extend that drug’s patent, a panel of European judges has ruled.
Celgene subsidiary Abraxis Bioscience had argued that the patent on its anti-cancer therapy Abraxane (paclitaxel) should be extended because its combination of paclitaxel and nanoparticles—which the company dubbed “nab-paclitaxel” was a fundamentally different approach to treatment.
But judges on the European Court of Justice disagreed in a preliminary ruling, saying that the mere addition of nanoparticles didn’t change Abraxane’s “active ingredient” because the additions had no therapeutic effect.
Upcoming Events
-
21Oct